Table 2 Comparison between smokers and non-smokers AS groups regarding demographic and clinical data
Demographic data | Group 1 (n = 20) | Group 2 (n = 30) | t/x2# | P value |
|---|---|---|---|---|
Gender | ||||
 Male: no. (%) | 20 (100.0%) | 19 (63.3%) | 9.402# | 0.002* |
 Female: no. (%) | 0 (0.0%) | 11 (36.7%) | ||
Age (years): range (mean) | 24-53 [33.85 ± 7.36] | 20-51 [34.57 ± 8.99] | 0.088 | 0.768 |
Duration of symptoms (years): range (mean) | 6-29 [13.30 ± 5.97] | 6-25 [13.20 ± 5.81] | 0.003 | 0.953 |
Parameters | Smokers (n = 20) | Non smokers (n = 30) | t/x2# | p value |
1. Spinal mobility | ||||
 Schober test (cm) | 2.70 ± 0.64 | 2.68 ± 0.96 | 0.005 | 0.946 |
 Chest expansion (cm) | 2.68 ± 0.41 | 3.42 ± 0.57 | 24.989 | < 0.001** |
 Occipt to wall distance (cm) | 10.90 ± 5.23 | 1.43 ± 3.50 | 58.983 | < 0.001** |
2. Disease activity indices | ||||
 BASDAI | 5.49 ± 0.36 | 3.65 ± 0.72 | 111.720 | < 0.001** |
 BASFI | 5.54 ± 0.58 | 4.15 ± 0.78 | 46.203 | < 0.001** |
 ASDAS | 4.06 ± 0.32 | 3.12 ± 0.56 | 45.972 | < 0.001** |
3. Radiological assessment | ||||
 Sacroilitis grade | ||||
  Grade 2 | 1 (5%) | 10 (33.3%) | 7.761# | 0.021* |
  Grade 3 | 9 (45%) | 14 (46.7%) | ||
  Grade 4 | 10 (50%) | 6 (20%) | ||
  mSASSS | 57.85 ± 9.01 | 33.80 ± 13.23 | 50.346 | < 0.001** |
4. Laboratory data | ||||
 ESR (mm/h) | 59.45 ± 21.21 | 45.90 ± 20.76 | 5.027 | 0.029* |
 CRP (mg/l) | 50.90 ± 7.35 | 24.47 ± 20.29 | 31.035 | < 0.001** |
3. Extra articular manifestations | ||||
 Uveitis | 2 (10.0%) | 1 (3.3%) | 2.405# | 0.662 |
3. Current medications | ||||
 NSAIDS | 16 (80%) | 18 (60%) | 2.206# | 0.137 |
 DMARDS | ||||
  Methotrexate | 3 (15%) | 2 (6.7%) | 0.952# | 0.621 |
  Sulfasalazine | 1 (5%) | 2 (6.7%) |  |  |
 Biologics | ||||
  Adalimumab | 2 (10%) | 5 (16.7%) | 0.965# | 0.617 |
  Etanercept | 17 (85%) | 22 (73.3%) |  |  |
 Corticosteriods | 0 (0.0%) | 1 (3.3%) | 0.680# | 0.409 |